A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00419250
Recruitment Status : Completed
First Posted : January 8, 2007
Last Update Posted : October 31, 2016
Information provided by (Responsible Party):
Celgene Corporation